CA2560844C - Pharmaceutical agent containing hyaluronan as an active ingredient - Google Patents

Pharmaceutical agent containing hyaluronan as an active ingredient Download PDF

Info

Publication number
CA2560844C
CA2560844C CA2560844A CA2560844A CA2560844C CA 2560844 C CA2560844 C CA 2560844C CA 2560844 A CA2560844 A CA 2560844A CA 2560844 A CA2560844 A CA 2560844A CA 2560844 C CA2560844 C CA 2560844C
Authority
CA
Canada
Prior art keywords
hyaluronan
expression
disease
cytokine
neural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2560844A
Other languages
English (en)
French (fr)
Other versions
CA2560844A1 (en
Inventor
Akira Asari
Hiroko Yamanokuchi
Tadahiko Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GLYCOSCIENCE LABORATORIES Inc
Shiseido Co Ltd
Original Assignee
GLYCOSCIENCE LABORATORIES Inc
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2005277918A external-priority patent/JP2007084509A/ja
Priority claimed from JP2005297991A external-priority patent/JP2007106688A/ja
Priority claimed from JP2005348017A external-priority patent/JP2007153761A/ja
Application filed by GLYCOSCIENCE LABORATORIES Inc, Shiseido Co Ltd filed Critical GLYCOSCIENCE LABORATORIES Inc
Publication of CA2560844A1 publication Critical patent/CA2560844A1/en
Application granted granted Critical
Publication of CA2560844C publication Critical patent/CA2560844C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CA2560844A 2005-09-26 2006-09-25 Pharmaceutical agent containing hyaluronan as an active ingredient Expired - Fee Related CA2560844C (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2005-277918 2005-09-26
JP2005277918A JP2007084509A (ja) 2005-09-26 2005-09-26 細胞賦活剤
JP2005297991A JP2007106688A (ja) 2005-10-12 2005-10-12 サイトカイン関連遺伝子及びケモカイン関連遺伝子の発現抑制剤
JP2005-297991 2005-10-12
JP2005348017A JP2007153761A (ja) 2005-12-01 2005-12-01 シナプス伝達促進剤及びシナプス保護剤
JP2005-348017 2005-12-01

Publications (2)

Publication Number Publication Date
CA2560844A1 CA2560844A1 (en) 2007-03-26
CA2560844C true CA2560844C (en) 2011-05-17

Family

ID=37667620

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2560844A Expired - Fee Related CA2560844C (en) 2005-09-26 2006-09-25 Pharmaceutical agent containing hyaluronan as an active ingredient

Country Status (7)

Country Link
EP (1) EP1767211B1 (no)
AR (1) AR056091A1 (no)
AT (1) ATE552005T1 (no)
BR (1) BRMU8603015U (no)
CA (1) CA2560844C (no)
NO (1) NO20064337L (no)
RU (1) RU2342148C2 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008068854A1 (ja) 2006-12-05 2008-06-12 Glycoscience Laboratories, Inc. 変形性関節症の治療剤
JP5117110B2 (ja) * 2007-05-28 2013-01-09 生化学工業株式会社 Ｉ型アレルギー疾患治療剤
EP2818172A4 (en) * 2012-02-22 2016-02-17 Hyaluronan Res Inst Inc TLR4 MEDIUM, TISSUE HOMEOSTAT, HEPATOCYTE GROWTH FACTOR INDUCTOR, TISSUE-DISAPPEARING AGENT, AND SIRTUINE INDUCTOR WITH HYALURONIC ACID FRAGMENTS AS ACTIVE AGENTS THEREOF
IT201600079773A1 (it) * 2016-07-29 2018-01-29 Matteo Bevilacqua Composizioni contenenti oligosaccaridi di acido ialuronico (HA4), condroitin solfato (CS2-4) ed eparan solfato (HS2-4), triterpeni pentaciclici e derivati per uso medico curativo e metodo per la preparazione di tali composizioni.
EP4085905B1 (en) * 2021-05-07 2024-02-21 TRB Chemedica AG Hyaluronic acid for use in preventing or treating neurological dysfunction of nerves or nerve cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013641A (en) * 1995-09-28 2000-01-11 Sangstat Medical Corporation Use of hyaluronic acid as an immunosuppressant
JP4195107B2 (ja) * 1996-02-16 2008-12-10 生化学工業株式会社 ストレス蛋白質発現増強剤
IT1309588B1 (it) * 1999-03-05 2002-01-24 Altergon Sa Cerotto con spessore sottile contenente betametasone ed acidoialuronico per il trattamento di psoriasi, dermatite, dermatosi.
JP2003089647A (ja) * 1999-03-10 2003-03-28 Takada Seiyaku Kk 関節性疾患治療剤
US7507723B2 (en) * 2000-07-07 2009-03-24 Seikagaku Corporation Hyaluronic acid oligosaccharide fractions and drugs containing the same
US6537968B1 (en) * 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
US7060691B2 (en) * 2002-10-10 2006-06-13 Giuseppe Petrigni Pharmaceutical colloidal preparation useful in the treatment of respiratory diseases
US7511026B2 (en) * 2003-03-25 2009-03-31 Seikagaku Corporation Therapeutic agent for nerve damage
HUP0303779A2 (en) * 2003-11-20 2006-02-28 Richter Gedeon Vegyeszet Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex
DE102004002001A1 (de) * 2004-01-14 2005-08-11 Reinmüller, Johannes, Dr.med. Mittel zur Behandlung von entzündlichen Erkrankungen

Also Published As

Publication number Publication date
RU2006134169A (ru) 2008-03-27
NO20064337L (no) 2007-03-27
RU2342148C2 (ru) 2008-12-27
AR056091A1 (es) 2007-09-19
EP1767211A1 (en) 2007-03-28
EP1767211B1 (en) 2012-04-04
BRMU8603015U (pt) 2007-12-11
CA2560844A1 (en) 2007-03-26
ATE552005T1 (de) 2012-04-15

Similar Documents

Publication Publication Date Title
Muto et al. Engagement of CD44 by hyaluronan suppresses TLR4 signaling and the septic response to LPS
CA2560844C (en) Pharmaceutical agent containing hyaluronan as an active ingredient
EP2429533B1 (en) Sulphated hyaluronic acids as regulator agents of the cytokine activity
JPH06507635A (ja) 病理学的過程の予防および／または治療用組成物
Jiang et al. Immunological regulatory effect of flavonoid baicalin on innate immune toll-like receptors
Guo et al. Fumigaclavine C ameliorates dextran sulfate sodium-induced murine experimental colitis via NLRP3 inflammasome inhibition
CN101300031A (zh) 用sdf-1治疗和/或预防神经疾病
Sabatino et al. Impact of IL-9 and IL-33 in mast cells
JP4754532B2 (ja) ヒアルロン酸オリゴ糖を有効成分とする治療剤
Feng et al. Polysaccharopeptide exerts immunoregulatory effects via MyD88-dependent signaling pathway
US20070099867A1 (en) Pharmaceutical agent containing hyaluronan as an active ingredient
Almeida et al. Statin pretreatment in experimental acute pancreatitis
JP2010510298A (ja) Ｔｎｆおよびｉｌ−１２のうちの少なくとも一方の過剰発現に関連する疾病の予防または治療のための組成物
US20070225251A1 (en) Method for Treating or Inhibiting the Effects of Injuries or Diseases that Result in Neuronal Degeneration
Ma et al. Activin A regulates activities of peripheral blood natural killer cells of mouse in an autocrine and paracrine manner
JP4022659B2 (ja) 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤
JP4195107B2 (ja) ストレス蛋白質発現増強剤
CN116019813A (zh) Vesatolimod在制备预防和/或治疗中枢神经系统疾病的药物中的应用
CN1939336A (zh) 含有透明质酸作为活性成分的药物试剂
Peters-Golden Do anti-leukotriene agents inhibit asthmatic inflammation?
Zhang et al. The role of Sonic Hedgehog pathway in the development of spinal cord injury in rat model
JP2007106688A (ja) サイトカイン関連遺伝子及びケモカイン関連遺伝子の発現抑制剤
Izeboud et al. Suppression of the acute inflammatory response of porcine alveolar‐and liver macrophages
Sadeghian et al. MedBulletin
Nagamoto et al. AB0036 BUTYRIC ACID SUPPRESSES MIGRATION OF MONOCYTE-DERIVED DENDRITIC CELLS BY INHIBITING MDIA1-MEDICATED ACTIN POLYMERIZATION

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140925